High post-exposure prophylaxis uptake but low completion rates and HIV testing follow-up in health workers, Harare, Zimbabwe.


Journal

Journal of infection in developing countries
ISSN: 1972-2680
Titre abrégé: J Infect Dev Ctries
Pays: Italy
ID NLM: 101305410

Informations de publication

Date de publication:
30 04 2021
Historique:
received: 28 11 2019
accepted: 04 06 2020
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 15 12 2021
Statut: epublish

Résumé

Health care workers (HCWs), especially from sub-Saharan Africa, are at risk of occupational exposure to HIV. Post exposure prophylaxis (PEP) can reduce this risk. There is no published information from Zimbabwe, a high HIV burden country, about how PEP works. We therefore assessed how the PEP programme performed at the Parirenyatwa Hospital, Harare, Zimbabwe, from 2017-2018. This was a cohort study using secondary data from the staff clinic paper-based register. The chi square test and relative risks were used to assess associations. There were 154 HCWs who experienced occupational injuries. The commonest group was medical doctors (36%) and needle sticks were the most frequent type of occupational injury (74%). The exposure source was identified in 114 (74%) occupational injuries: 91% of source patients were HIV-tested and 77% were HIV-positive. All but two HCWs were HIV-tested, 148 were eligible for PEP and 142 (96%) started triple therapy, all within 48 hours of exposure. Of those starting PEP, 15 (11%) completed 28 days, 13 (9%) completed < 28 days and in the remainder PEP duration was not recorded. There were no HCW characteristics associated with not completing PEP. Of those starting PEP, 9 (6%) were HIV-tested at 6-weeks, 3 (2%) were HIV-tested at 3-months and 1 (< 1%) was HIV-tested at 6-months: all HIV-tests were negative. While uptake of PEP was timely and high, the majority of HCWs failed to complete the 28-day treatment course and even fewer attended for follow-up HIV-tests. Various changes are recommended to promote awareness of PEP and improve adherence to guidelines.

Identifiants

pubmed: 33956657
doi: 10.3855/jidc.12214
pmc: PMC8655953
mid: NIHMS1760336
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

559-565

Subventions

Organisme : FIC NIH HHS
ID : D43 TW009539
Pays : United States

Informations de copyright

Copyright (c) 2021 Fadzai Mushambi, Collins Timire, Anthony D Harries, Hannock Tweya, Tafadzwa Priscilla Goverwa-Sibanda, Stanley Mungofa, Tsitsi Apollo.

Déclaration de conflit d'intérêts

No Conflict of Interest is declared

Références

Med Pr. 2010;61(3):315-22
pubmed: 20677431
Pan Afr Med J. 2014 Oct 20;19:172
pubmed: 25815093
N Engl J Med. 2009 Oct 29;361(18):1768-75
pubmed: 19864675
J Hosp Infect. 2017 Jul;96(3):276-280
pubmed: 28274607
BMJ. 2018 Nov 29;363:k4928
pubmed: 30498074
Medicine (Baltimore). 2018 Sep;97(36):e12226
pubmed: 30200145
N Engl J Med. 1997 Nov 20;337(21):1485-90
pubmed: 9366579
J Infect Prev. 2018 Jul;19(4):184-189
pubmed: 30013623
South Afr J HIV Med. 2019 May 22;20(1):958
pubmed: 31205779
Pan Afr Med J. 2018 Mar 19;29:158
pubmed: 30050622
J Assoc Nurses AIDS Care. 2016 Sep-Oct;27(5):727-30
pubmed: 27425796
Trop Doct. 2007 Jan;37(1):4-6
pubmed: 17326876
BMC Infect Dis. 2017 Aug 31;17(1):602
pubmed: 28859613
Am J Infect Control. 2016 Aug 1;44(8):879-85
pubmed: 27021510
PLoS One. 2018 Oct 25;13(10):e0201695
pubmed: 30359370
Curr Opin Infect Dis. 2018 Feb;31(1):14-24
pubmed: 29232277
J Infect Dev Ctries. 2017 Jan 30;11(1):65-72
pubmed: 28141592
Pan Afr Med J. 2018 Jul 27;30:233
pubmed: 30574252
AIDS Res Ther. 2017 Apr 21;14(1):23
pubmed: 28431556
Hum Resour Health. 2019 Jun 7;17(1):41
pubmed: 31174543
J Med Internet Res. 2014 Oct 17;16(10):e222
pubmed: 25326646
Bull World Health Organ. 2007 Nov;85(11):867-72
pubmed: 18038077

Auteurs

Fadzai Mushambi (F)

Emergency Department, Parirenyatwa Group of Hospitals, Harare, Zimbabwe. fadziemush@gmail.com.

Collins Timire (C)

Ministry of Health and Child Care, National AIDS and TB Program, Harare, Zimbabwe.

Anthony D Harries (AD)

The Union, Paris, France.

Hannock Tweya (H)

The Union, Paris, France.

Tafadzwa Priscilla Goverwa-Sibanda (TP)

AIDS Healthcare Foundation, Harare, Zimbabwe.

Stanley Mungofa (S)

Health Services Board, Harare, Zimbabwe.

Tsitsi Apollo (T)

Ministry of Health and Child Care, National AIDS and TB Program, Harare, Zimbabwe.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH